Metabolism Disorder TRIZ Cases

GspA peptide stimulates endogenous GLP-1 secretion to resolve contradictions in insulin sensitivity and glucose production.

Small molecules inhibit JAK1 or HSP90 to upregulate CPS1, boosting ureagenesis and reducing ammonia accumulation without dietary restrictions.

A fatty acid-polymer-photosensitizer conjugate targets duodenal K cells to reduce GIP secretion via light-induced oxidative stress.

A multi-strain probiotic composition reduces total cholesterol, LDL, and triglyceride levels.

Phytic acid replaces toxic agents in chitosan capsules, enabling pH-dependent sustained release and high encapsulation efficiency.

Combines trans-Gnetin H with mitochondrial complex I inhibitors to force apoptosis in p53-deficient cancer cells.

Extracting the calcemic A-ring from vitamin D3 yields CD-ring derivatives that inhibit SREBP without residual VDR binding activity.

Segmented anti-cKIT antibody fragments selectively ablate hematopoietic stem cells while minimizing mast cell degranulation.

Peptides derived from the PCSK9 catalytic domain bind to LDL receptors to prevent their degradation and maintain cell surface levels.

Double-acylated GLP-1 derivatives attach albumin binding moieties to lysine residues via linkers.

Tetrahydro-naphthalene derivatives inhibit MTP to reduce VLDL and LDL production, addressing limited efficacy in existing hyperlipidemia treatments.

Sulfur-containing antioxidants prevent oxidative degradation of cysteine proteases in gastric fluid, maintaining enzyme activity for oral administration.

AR-42 HDAC inhibitor suppresses muscle wasting and adipose tissue loss to maintain body weight despite cancer progression.

Position 1 substitution resolves solubility and stability contradictions, enabling reliable hypoglycemia treatment.

Replacing column chromatography with a stirring separation process increases extraction throughput and yields effective wound healing extracts.

Compounds mimicking the E4orf1 protein increase glucose uptake and insulin sensitivity without triggering preadipocyte differentiation or increasing adiposity.

Combining a glucagon receptor antagonist with a cholesterol absorption inhibitor manages diabetes treatment.

Merging CETP and SGLT2 inhibition into one daily dose improves glycemic control without weight gain.

Novel dihydrazide compounds featuring disulfide bonds enable flexible molecular structures for medical hydrogel synthesis and drug delivery carriers.

Zn2+ ions dissociate growth factors from soluble receptors, resolving low oral bioavailability caused by receptor binding.

Combining GDF8 and Activin A inhibitors reduces fat mass and increases muscle volume without altering total body weight.

Hydrophobic chromatography of sugar cane molasses yields polyphenol extracts that reduce postprandial glucose and insulin spikes without causing hypoglycemia.

A beverage precursor uses ultra-fine tea particles to deliver catechins efficiently upon contact with hot water.

Nanolipid vehicles stabilize apolactoferrin against degradation while maintaining high iron binding capacity.

Covalent insulin receptor partial agonist dimers activate hepatic receptors to regulate glucose levels.

Culturing human definitive endoderm with FGF-2, retinoic acid, and activin A to generate pancreatic endocrine cells.

Differentiated 3D brown adipose aggregates replace bariatric surgery by autonomously increasing energy expenditure and improving glucose tolerance.

High shear dispersion breaks hydrophobic plant sterols into sub-30 µm microparticles within an aqueous polyphenol-rich herbal tea extract.

Carbon dioxide gas dissolves in the effervescent beverage to form carbonic acid, suppressing bitterness without cyclodextrin additives.

Magnesium-potassium dimeric double metal salts stabilize hydroxycitric acid against acidic lactonization, enabling stable dry powder formulations.

Converting ferrous hydroxide via controlled oxidation reduces manufacturing costs and product loss from extensive washing.

Schizochytrium mangrovei strain CNCM I-4702 accumulates docosahexaenoic acid and palmitic acid through heterotrophic fermentation.

Segmented tablet core and coating deliver distinct release profiles for metformin and DPP-4 inhibitors.

High sugar concentrations create a hypertonic environment that prevents gelation and chemical degradation, enabling stable delivery in bi-hormonal pumps.

A holotoxin partially blocks the ER translocon to prevent retrotranslocation of functional misfolded proteins.

Diethyl azelate treats insulin resistance by modulating immune function, reducing blood glucose levels without causing weight gain or hypoglycemia.

Zinc-insulin complexes provide inherent buffering capacity, eliminating external agents to maintain pH stability across a 6.0 to 9.0 range.

Modified GIP analogues extend in vivo half-life and reduce antagonistic fragment production by resisting proteolytic cleavage.

Replacing benzyl with tetrahydropyranyl simplifies deprotection, while McMurry reactions selectively form Z-isomers to resolve tedious separation bottlenecks.

A lipidated amide insulin prodrug uses a dipeptide linker to bind plasma proteins for controlled release.

Fstl-1 polypeptide activates Akt signaling to protect cardiac tissue, resolving the contradiction between standard care and effective apoptosis prevention.

PI3K-p110δ inhibitors selectively constrain autoreactive B cell signaling to restore anergy.

Saccharomyces boulardii yeast cells reduce adipose mass and liver lipid content without altering intestinal bacterial balance.

M16αα reduces adverse reactions from multiple drugs by simultaneously improving glycemic control and lipid profiles.

Engineered non-pathogenic bacteria use a type three secretion system to deliver polypeptides directly into target cells.

Merging metformin and fenfluramine into single compounds resolves the glycemic control versus weight loss trade-off in type 2 diabetes treatment.

Resin adsorption removes heavy metals from crude plant extracts, reducing ethanol consumption during subsequent precipitation steps.